UniProtKB/Swiss-Prot P40337: Variant p.His110Tyr

von Hippel-Lindau disease tumor suppressor
Gene: VHL
Feedback?

Variant information Variant position:

110 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Histidine (H) to Tyrosine (Y) at position 110 (H110Y, p.His110Tyr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from medium size and polar (H) to large size and aromatic (Y) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs17855706 [ dbSNP | Ensembl ]

Sequence information Variant position:

110 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

213 The length of the canonical sequence.
Location on the sequence:

NFDGEPQPYPTLPPGTGRRI H SYRGHLWLFRDAGTHDGLLV The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         NFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLV

                              NFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTYDGLLV

Mouse                         NFDGEPQPYPILPPGTGRRIHSYRGHLWLFRDAGTHDGLLV

Rat                           NFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLV

Caenorhabditis elegans        NPSKQPTKYGTLAQKKYLDIKTFKDHPWVARRSFDGCKVLV

Drosophila                    CERERENMYLTLKPFEEVRVNTFTTHSWLFRDYYTGERMHV

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 213	von Hippel-Lindau disease tumor suppressor
Region	100 – 155	Involved in binding to CCT complex
Mutagenesis	98 – 98	Y -> N. No interaction with HIF1A. No HIF1A degradation.
Beta strand	106 – 112

Literature citations
The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2); VARIANT TYR-110;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.